Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update

Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update

Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in childhood. Current treatment options for ADHD include pharmacological treatment (stimulants, non-stimulants, anti-depressants, anti-psychotics), psychological treatment (behavioral therapy with or witho...

Full description

Saved in:
Bibliographic Details
Main Authors: Hannah W Haddad, Paul B. Hankey, Jimin Ko, Zahaan Eswani, Pravjit Bhatti, Amber N. Edinoff, Adam M. Kaye, Alan D. Kaye
Format: Article
Language:English
Published: Open Medical Publishing 2022-07-01
Series:Health Psychology Research
Online Access:https://doi.org/10.52965/001c.37018
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.52965/001c.37018

Similar Items